All In Biotech

Drug Trial Radar · NCT07926217

High-Dose Versus Standard-Dose Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy

Immunogenicity of High-Dose Versus Standard-Dose Inactivated Influenza Vaccine in Patients With Hematologic Malignancies Receiving B-Cell-Depleting Therapy: A Randomized Trial With Blinded Laboratory Outcome Assessment

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 2, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Sung-Han KimAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized trial will compare the immune responses to high-dose and standard-dose influenza vaccines in 60 adults with blood cancers (hematologic malignancies) who have received B-cell-depleting therapy. Participants will be assigned by chance, in a 1:1 ratio, to receive one of the two vaccines. Antibody and T-cell responses will be measured before and after vaccination. Participants and their treating clinicians will know which vaccine is given. Laboratory staff who measure and interpret the immune responses will not know which vaccine each participant received until the laboratory results are finalized.

Conditions

  • Hematologic Malignancy
  • Influenza

Interventions

  • High-dose inactivated influenza vaccineBiological

    Trivalent inactivated influenza vaccine containing 60 micrograms of hemagglutinin per strain, administered as a single intramuscular injection on Day 0. It contains four times the hemagglutinin antigen per strain of the standard-dose vaccine.

  • Standard-dose inactivated influenza vaccineBiological

    Trivalent inactivated influenza vaccine containing 15 micrograms of hemagglutinin per strain, administered as a single intramuscular injection on Day 0. It is the comparator for the high-dose vaccine.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion Rate at Day 28 After Influenza VaccinationTime frame: Day 28 (±7 days) after vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.